menu
    • menu
    [{"orgOrder":0,"company":"Philips","sponsor":"Imunon","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2012","type":"Inapplicable","leadProduct":"Doxorubicin Hydrochloride","moa":"DNA topoisomerase II alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Philips","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philips \/ Philips","highestDevelopmentStatusID":"8","companyTruncated":"Philips \/ Philips"},{"orgOrder":0,"company":"Philips","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"NETHERLANDS","productType":"Undisclosed","year":"2016","type":"Inapplicable","leadProduct":"Blue Light Photodynamic Therapy","moa":"Undisclosed","graph1":"Dermatology","graph2":"Undisclosed","graph3":"Philips","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philips \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Philips \/ Undisclosed"},{"orgOrder":0,"company":"Philips","sponsor":"William Chu, MD, MSc, FRCPC","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Capecitabine","moa":"RNA | DNA | Thymidylate synthase","graph1":"Oncology","graph2":"Undisclosed","graph3":"Philips","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Philips \/ William Chu, MD, MSc, FRCPC","highestDevelopmentStatusID":"1","companyTruncated":"Philips \/ William Chu, MD, MSc, FRCPC"}]

    Find Clinical Drug Pipeline Developments & Deals by Philips

    Menu

    Philips

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Philips

                            Netherlands arrow
                            Aquaexpo
                            Not Confirmed

                            Philips

                            Netherlands arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Blue Light Photodynamic Therapy

                            Therapeutic Area : Dermatology

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Blue Light (453 nm) Treatment for Mild Psoriasis Vulgaris Over Three Months Compared to...

                            Details : Blue Light Photodynamic Therapy is a drug candidate, which is currently being evaluated in clinical studies for the treatment of Psoriasis.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 12, 2016

                            Lead Product(s) : Blue Light Photodynamic Therapy

                            Therapeutic Area : Dermatology

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Philips

                            Netherlands arrow
                            Aquaexpo
                            Not Confirmed

                            Philips

                            Netherlands arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : William Chu, MD, MSc, FRCPC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Magnetic Resonance-Guided High Intensity Focused Ultrasound for Recurrent Rectal Cancer

                            Details : Xeloda (Capecitabine) is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Rectal Neoplasms.

                            Product Name : Xeloda

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            August 19, 2015

                            Lead Product(s) : Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : William Chu, MD, MSc, FRCPC

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Philips

                            Netherlands arrow
                            Aquaexpo
                            Not Confirmed

                            Philips

                            Netherlands arrow
                            Aquaexpo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Imunon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            MRI Guided High Intensity Focused Ultrasound (HIFU) and ThermoDox for Palliation of Painful Bone Metastases

                            Details : Doxorubicin is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Bone Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            July 16, 2012

                            Lead Product(s) : Doxorubicin Hydrochloride

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Imunon

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth